
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Sickle Cell Disease Treatment Market**

According to Intelli, the U.S. Sickle Cell Disease Treatment Market size was valued at USD 825.33 Million in 2024 and is projected to reach USD 3,556.78 Million by 2032, growing at a CAGR of 20.84% from 2025 to 2032.



Sickle Cell Disease (SCD) is a group of inherited blood disorders characterized by the production of abnormally shaped red blood cells, known as sickle cells. The crescent-shaped sickle cells in SCD are rigid and sticky compared to normal round red blood cells. This abnormal shape makes it difficult for them to flow smoothly through the blood vessels, especially the small ones. When these sickle cells clump together or get stuck, they block the normal flow of blood, which disrupts the delivery of oxygen to tissues and organs throughout the body. This blockage causes intense pain, known as sickle cell crises, which can last from hours to days. The reduced blood flow and oxygen supply can also lead to organ damage over time, as organs like the kidneys, liver, heart, and lungs don't get the oxygen they need to function properly. Additionally, because sickle cells are more fragile and break down faster than normal red blood cells, their destruction leads to a shortage of healthy red blood cells, or anemia, which further contributes to fatigue and weakness. Common symptoms include episodes of severe pain (called sickle cell crises), fatigue, anemia, swelling in the hands and feet, frequent infections, and delayed growth in children. Risk factors for SCD primarily include family history including genetic mutations. While there is no universal cure for SCD, treatment options include pain management, blood transfusions, hydroxyurea to reduce the frequency of crises, and in some cases, stem cell transplants. Early diagnosis and ongoing medical care are crucial for managing the disease and improving quality of life.

**U.S. Sickle Cell Disease Treatment Market Definition**

The U.S. Sickle Cell Disease Treatment Market refers to the sector focused on the development, production, and delivery of medical interventions, including pharmaceuticals, blood transfusions, gene therapies, and supportive care, aimed at managing and treating sickle cell disease in affected populations. This market encompasses a range of medical interventions aimed at managing and treating SCD, a genetic blood disorder. This market includes pharmaceuticals, therapies, diagnostic tools, and medical devices specifically designed for individuals suffering from SCD. It also A close-up of hands holding a tablet and a pen

Description automatically generatedincludes the development and adoption of innovative treatments aimed at providing a more permanent solution for SCD.

**U.S. Sickle Cell Disease Treatment Market Overview**

​The U.S. sickle cell disease treatment market is experiencing significant growth, driven by several key factors. Advancements in gene therapies, particularly CRISPR-based treatments, hold promising potential as curative options for sickle cell disease by directly modifying the genetic material of affected cells. These therapies aim to address the root cause of the disease by correcting the abnormal hemoglobin gene, potentially offering a long-term or permanent solution. Moreover, the rising prevalence of sickle cell disease, especially within American communities, highlights the critical demand for more effective treatment options to address the growing burden of the disease. Ongoing research and development in the field of sickle cell disease are continually introducing new and innovative therapies, further diversifying the available treatment options. These advancements include novel drugs, gene therapies, and alternative approaches to managing the disease. As these new therapies become more accessible, they are expected to enhance treatment effectiveness and offer more targeted solutions for patients. Collectively, these factors, rising research breakthroughs, increased awareness, and the need for better care, are driving the expansion of the market.

**U.S. Sickle Cell Disease Treatment Market Segmentation**

The U.S. Sickle Cell Disease Treatment Market can be segmented across several key categories, helping stakeholders better understand market dynamics and identify growth opportunities.

**U.S. Sickle Cell Disease Treatment Market, By Treatment Type**

* **Pharmacotherapy**
* **Blood Transfusions**
* **Bone Marrow/Stem Cell Transplantation**
* **Gene Therapy**
* **Supportive Care**

**​**The U.S. sickle cell disease treatment market is segmented by treatment type into pharmacotherapy, blood transfusions, bone marrow/stem cell transplantation, gene therapy, and supportive care. Blood transfusions accounted for the largest share of the A close-up of hands holding a tablet and a pen

Description automatically generatedU.S. sickle cell disease market. Meanwhile, pharmacotherapy, featuring established drugs like hydroxyurea and innovative therapies such as voxelotor and crizanlizumab, is emerging as the fastest-growing segment, fueled by increasing demand for more convenient and less invasive treatment options. Gene therapies, such as the FDA-approved Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), represent groundbreaking advancements with the potential to cure sickle cell disease by addressing its genetic root cause. Despite their promise, the widespread adoption of these therapies has been limited due to their high costs and the complex procedures required for administration, which pose challenges for both patients and healthcare systems. Bone marrow and stem cell transplantation remain limited due to donor availability and patient eligibility criteria. Supportive care continues to play a vital role in managing symptoms and improving patient quality of life.

**U.S. Sickle Cell Disease Treatment Market, By Disease Type**

* **Sickle Cell Anemia**
* **Sickle Hemoglobin-C Disease**
* **Sickle Beta-Plus Thalassemia**
* **Sickle Beta-Zero Thalassemia**

The U.S. sickle cell disease treatment market is categorized by disease type into four main subtypes, each with varying severity and treatment needs. Sickle Cell Anemia, the most severe and common form, dominates the market due to its high prevalence and the intensive medical care it requires. Sickle Hemoglobin-C Disease typically presents milder symptoms than sickle cell anemia but still requires regular monitoring and supportive treatment, contributing to a moderate share of the market. Sickle Beta-Plus Thalassemia and Sickle Beta-Zero Thalassemia are less common but often more complex in management, especially and Sickle Beta-Zero Thalassemia which can mimic the severity of Sickle Hemoglobin-C disease. These subtypes, though representing a smaller portion of the patient population, create demand for personalized and targeted therapies.

**U.S. Sickle Cell Disease Treatment Market, By Route of Administration**

* **Oral**
* **Intravenous**
* **Subcutaneous**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. sickle cell disease treatment market is segmented by route of administration into oral, intravenous (IV), and subcutaneous delivery methods, each playing a distinct role in patient care. Oral administration holds a significant share of the market, driven by the widespread use of medications. Intravenous therapies, including blood transfusions and specific monoclonal antibodies, continue to play a vital role in treating acute complications of sickle cell disease, offering rapid symptom relief and making them indispensable in hospital and emergency care settings. Meanwhile, subcutaneous administration is becoming increasingly popular with the introduction of targeted treatments like crizanlizumab. These therapies provide the convenience of outpatient delivery and reduced dosing frequency, enhancing patient comfort and treatment adherence. The diversity in administration routes reflects the need for flexible treatment options tailored to the severity of symptoms, treatment accessibility, and patient preferences, ultimately enhancing the quality and efficiency of care.

**U.S. Sickle Cell Disease Treatment Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

The U.S. sickle cell disease treatment market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies, each contributing uniquely to patient access and treatment delivery. Hospital pharmacies dominate the market, especially for administering complex treatments like blood transfusions, monoclonal antibodies, and gene therapies that require professional supervision. Retail pharmacies serve a vital function in providing easy access to oral medications like voxelotor, and L-glutamine, supporting consistent treatment and long-term disease management. At the same time, online pharmacies are gaining momentum as a practical and efficient alternative, enabling patients to conveniently refill prescriptions and receive medications at home, an especially important option for those facing mobility challenges or living in remote or underserved regions.

**Key Players**

The “U.S. sickle cell disease treatment market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Novartis AG, Pfizer Inc., A close-up of hands holding a tablet and a pen

Description automatically generatedBristol-Myers Squibb, Sanofi SA, F. Hoffmann-La Roche AG, Johnson & Johnson, Novo Nordisk, Vertex Pharmaceuticals, Medunik USA, CRISPR Therapeutics, GlycoMimetics, Inc., Bellicum Pharmaceuticals, Inc.,Agios Pharmaceuticals, Emmaus Life Sciences, Inc., Addmedica, Biogen, Graphite Bio among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Development**

* In 2025, Bristol-Myers Squibb has started a clinical trial for a new sickle cell disease treatment that targets the root causes of the condition. They are exploring targeted protein degraders, specifically molecular glue degraders to remove genetic regulators that suppress fetal hemoglobin (HbF) production, aiming to boost HbF levels and improve outcomes in sickle cell anemia.
* In 2024, Safi Biotherapeutics received Rare Pediatric Disease Designation and Orphan Drug Designation for their lab-made red blood cells (mRBCs), designed for chronic transfusions in sickle cell disease (SCD) patients.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. sickle cell disease treatment market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. sickle cell disease treatment market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. SICKLE CELL DISEASE TREATMENT MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. SICKLE CELL DISEASE TREATMENT MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY TREATMENT TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Pharmacotherapy

5.3 Blood Transfusions

5.4 Bone Marrow/Stem Cell Transplantation

5.5 Gene Therapy

5.6 Supportive Care

**6 U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE TYPE**

6.1 Overview

6.2 Sickle Cell Anemia

6.3 Sickle Hemoglobin-C Disease

6.4 Sickle Beta-Plus Thalassemia

6.5 Sickle Beta-Zero Thalassemia

**7 U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

7.1 Overview

7.2 Oral

7.3 Intravenous

7.4 Subcutaneous

1. **U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL**
   1. Overview
   2. Hospital Pharmacies
   3. Retail Pharmacies
   4. A close-up of hands holding a tablet and a pen

      Description automatically generatedOnline Pharmacies
2. **U.S. SICKLE CELL DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 Novartis AG**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Sanofi SA**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  4. **F. Hoffmann-La Roche AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Novo Nordisk**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Vertex Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Medunik USA**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  2. **CRISPR Therapeutics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **GlycoMimetics, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Bellicum Pharmaceuticals, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Agios Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Emmaus Life Sciences, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. A close-up of hands holding a tablet and a pen

     Description automatically generated**Addmedica**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Biogen**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **Graphite Bio**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research